Cargando…
Exploiting Necroptosis for Therapy of Acute Lymphoblastic Leukemia
Escape from chemotherapy-induced apoptosis is a hallmark of drug resistance in cancer. The recent identification of alternative programmed cell death pathways opens up for possibilities to circumvent the apoptotic blockade in drug resistant cancer and eliminate malignant cells. Indeed, we have recen...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6433701/ https://www.ncbi.nlm.nih.gov/pubmed/30941349 http://dx.doi.org/10.3389/fcell.2019.00040 |
_version_ | 1783406324413890560 |
---|---|
author | Mezzatesta, Caterina Bornhauser, Beat C. |
author_facet | Mezzatesta, Caterina Bornhauser, Beat C. |
author_sort | Mezzatesta, Caterina |
collection | PubMed |
description | Escape from chemotherapy-induced apoptosis is a hallmark of drug resistance in cancer. The recent identification of alternative programmed cell death pathways opens up for possibilities to circumvent the apoptotic blockade in drug resistant cancer and eliminate malignant cells. Indeed, we have recently shown that programmed necrosis, termed necroptosis, could be triggered to induce cell death in a subgroup of primary acute lymphoblastic leukemia (ALL) including highly refractory relapsed cases. In this review we focus on molecular mechanisms that drive drug resistance in ALL of childhood and discuss the potential of necroptosis activation to eradicate resistant disease. |
format | Online Article Text |
id | pubmed-6433701 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-64337012019-04-02 Exploiting Necroptosis for Therapy of Acute Lymphoblastic Leukemia Mezzatesta, Caterina Bornhauser, Beat C. Front Cell Dev Biol Cell and Developmental Biology Escape from chemotherapy-induced apoptosis is a hallmark of drug resistance in cancer. The recent identification of alternative programmed cell death pathways opens up for possibilities to circumvent the apoptotic blockade in drug resistant cancer and eliminate malignant cells. Indeed, we have recently shown that programmed necrosis, termed necroptosis, could be triggered to induce cell death in a subgroup of primary acute lymphoblastic leukemia (ALL) including highly refractory relapsed cases. In this review we focus on molecular mechanisms that drive drug resistance in ALL of childhood and discuss the potential of necroptosis activation to eradicate resistant disease. Frontiers Media S.A. 2019-03-19 /pmc/articles/PMC6433701/ /pubmed/30941349 http://dx.doi.org/10.3389/fcell.2019.00040 Text en Copyright © 2019 Mezzatesta and Bornhauser. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Cell and Developmental Biology Mezzatesta, Caterina Bornhauser, Beat C. Exploiting Necroptosis for Therapy of Acute Lymphoblastic Leukemia |
title | Exploiting Necroptosis for Therapy of Acute Lymphoblastic Leukemia |
title_full | Exploiting Necroptosis for Therapy of Acute Lymphoblastic Leukemia |
title_fullStr | Exploiting Necroptosis for Therapy of Acute Lymphoblastic Leukemia |
title_full_unstemmed | Exploiting Necroptosis for Therapy of Acute Lymphoblastic Leukemia |
title_short | Exploiting Necroptosis for Therapy of Acute Lymphoblastic Leukemia |
title_sort | exploiting necroptosis for therapy of acute lymphoblastic leukemia |
topic | Cell and Developmental Biology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6433701/ https://www.ncbi.nlm.nih.gov/pubmed/30941349 http://dx.doi.org/10.3389/fcell.2019.00040 |
work_keys_str_mv | AT mezzatestacaterina exploitingnecroptosisfortherapyofacutelymphoblasticleukemia AT bornhauserbeatc exploitingnecroptosisfortherapyofacutelymphoblasticleukemia |